GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
about
Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal womenAdjuvant Gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal womenFertility Protection in Female Oncology Patients: How Should Patients Be Counseled?How do chemotherapeutic agents damage the ovary?Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.Emerging gonadotropin-releasing hormone agonists.Fertility preservation in young cancer patients.Cryoconservation of Oocytes in a Patient with Breast Cancer and Intrauterine Early PregnancyEffects of GnRH agonist treatment on steroidogenesis and folliculogenesis in the ovary of cyclic mice.Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT.Retransplantation of cryopreserved ovarian tissue: the first live birth in GermanyGonadotropin-releasing hormone analog cotreatment for preservation of ovarian function.Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).Fertility-sparing surgery in early epithelial ovarian cancer: a viable option?Reproductive late effects in female survivors of childhood cancer.Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analoguesFertility in female survivors of Hodgkin's lymphoma.Pediatric and Teen Ovarian Tissue Removed for Cryopreservation Contains Follicles Irrespective of Age, Disease Diagnosis, Treatment History, and Specimen Processing Methods.Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis.Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in SurvivorsCombination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.Oncofertility in Canada: gonadal protection and fertility-sparing strategies.Fertility preservation in gynecological cancers.Fertility-preservation in endometrial cancer: is it safe? Review of the literature.Fertility conservation in breast cancer patients.Fertility sparing in cancer patients.Fertility preservation in women.Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.Operative techniques and complications of extraction and transplantation of ovarian tissue: the Erlangen experience.Late endocrine effects of childhood cancer.Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study GroupThe impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice.Fertility preservation in >1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques.Fertility preservation for patients with hematologic malignancies: The Korean Society for Fertility Preservation clinical guidelines.Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions.Fertility Preservation: Current and Future Perspectives for Oncologic Patients at Risk for Iatrogenic Premature Ovarian Insufficiency
P2860
Q24235150-30BFB2CF-2895-4B12-B3D5-A3BDA346E35DQ24241143-3CAB2F5E-DE6F-4620-9189-AA3FF5C5C3F4Q26771340-F712E8C1-B2C3-4356-9E3D-D25F85ED7020Q28267696-F233AD85-E9D1-4F66-A9F1-68F9BAC4642EQ28383280-CE381271-28FE-4CA1-8624-9622A9386553Q30360464-0152707B-5082-4005-A75D-FD6650180EAFQ33796122-7D9BCE2C-2640-4233-A6E5-E0EA39915D32Q33935418-4B0BCDA7-A076-4F23-B060-C224B6526989Q34209254-B207AF74-7F3C-40E1-9BAE-EBE3230E844DQ34388026-6B2DC61F-1BB9-4E87-97D4-5AFEDB1BEFA6Q34743455-1797CC95-8D54-42C3-B5B6-53960C655B1CQ35097386-1167E9E7-9099-41FB-AFB7-E31C4A9B0E6CQ35694239-BAF8D6B9-DA2D-4A7D-A945-4D1EEE36A3C7Q35776206-55B0EAFA-D4EB-4F2A-8BF4-420FE1E74B1EQ35835278-F64F163D-399D-4670-85CB-078F5968387EQ35864000-300D782B-EFBF-4E8A-9B2E-5356A13009B1Q35961728-ACB4A2A8-6013-4B30-A6B1-D754A2264895Q36010259-1388285F-0506-4CAA-A21A-00FBC32ADBFCQ36283790-EF5C9B65-781C-4175-8021-A8646BE31233Q36385937-DF511A95-1AD5-45C3-BF77-07D78E283DA1Q36404774-31107669-D1E6-4824-8DED-05C90D556C40Q36478738-A687E6A6-F730-4006-AB25-3E99F89C30F9Q36688597-7DA829DF-DD3F-4621-A10F-B7C923EC4316Q37364626-3E839433-57E7-463D-868B-D9BAF7186557Q37463014-540F6E59-A553-480D-8BAF-42432F045F9BQ37605349-DB7FDFF5-F106-4B64-8006-70B6C02E59AEQ37853557-EBA6D0E8-8281-45AE-B36B-7E53C19BBF1DQ37932564-AADB64EE-037C-4ECF-960C-476E317573A0Q38156039-15830E5F-59A4-40B4-A9D5-BD7892B14E30Q38397291-01865E58-BD44-4DEE-9B4E-860B622FDCD2Q38757529-1B2A0021-4843-48A7-B8F9-61C7012DAB30Q38794942-640F7FC2-F012-4A5C-8746-F0E3D7097F55Q39026680-828A9C92-B415-464A-B0F0-75B4A924BA92Q43122802-2DFAD4B5-C3A6-4179-A538-5E33F00DC1E1Q43519793-EA515852-3707-43D9-82E5-FCA666650B19Q45282136-132FE082-4EEC-4629-8F62-A0A0C346975EQ46590938-F074E858-40E7-4D9A-A037-F4F9284E0E57Q49627384-697628A7-C7CD-4023-9342-AA52A29B865FQ51306771-1FEB5C3E-FB4F-4A7D-A37E-0EC0DD3DFAAAQ57176379-00AB23A8-8256-44A1-AC3B-676F3E2CD5F0
P2860
GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GnRH-analogues and oral contra ...... in women during chemotherapy.
@en
GnRH-analogues and oral contra ...... in women during chemotherapy.
@nl
type
label
GnRH-analogues and oral contra ...... in women during chemotherapy.
@en
GnRH-analogues and oral contra ...... in women during chemotherapy.
@nl
prefLabel
GnRH-analogues and oral contra ...... in women during chemotherapy.
@en
GnRH-analogues and oral contra ...... in women during chemotherapy.
@nl
P2860
P356
P1476
GnRH-analogues and oral contra ...... n in women during chemotherapy
@en
P2093
Zeev Blumenfeld
P2860
P304
P356
10.1093/HUMUPD/DMN022
P577
2008-09-29T00:00:00Z